Key terms
About BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BLUE news
Apr 19
7:31pm ET
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Apr 08
10:00pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Mar 30
3:48pm ET
Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?
Mar 29
4:20am ET
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
Mar 29
3:08am ET
Bluebird Bio’s Hold Rating: Balancing Commercial Progress with Financial Restatements and Investor Concerns
Mar 28
5:35pm ET
bluebird bio, Inc. Class Action: Levi & Korsinsky LLP Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 – BLUE
Mar 27
7:29am ET
Bluebird Bio price target lowered to $4 from $5 at BofA
Mar 26
8:49pm ET
Bluebird Bio price target lowered to $3 from $4 at Wells Fargo
Mar 26
8:02pm ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Healthequity (HQY) and Bluebird Bio (BLUE)
Mar 26
7:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
Mar 26
5:25pm ET
Hold Rating on Bluebird Bio Amidst Gradual Patient Starts and Funding Steps
Mar 26
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 26, 2024
Mar 21
2:38am ET
Optimistic Outlook for Bluebird Bio: Buy Rating Affirmed on Extended Financial Runway and Profitability Prospects
Mar 19
8:56am ET
Bluebird Bio price target lowered to $1.68 from $3 at Wedbush
Mar 14
12:50pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Mar 14
11:41am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Mar 11
8:15am ET
Bluebird Bio signs Medicaid outcomes-based agreement for Lyfgenia
Mar 01
1:20am ET
Strong Market Potential for Bluebird Bio’s Lyfgenia Backed by High Demand and Differentiation Factors
Feb 01
12:40am ET
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Alcon (ALC)
Yesterday
10:30pm ET
May 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BLUE
Yesterday
9:45pm ET
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Shareholders
Yesterday
9:45pm ET
bluebird bio, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE
Yesterday
7:43pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE
Yesterday
6:15pm ET
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit – BLUE
Yesterday
5:30pm ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
Yesterday
1:45pm ET
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders
Yesterday
1:40pm ET
bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BLUE
Yesterday
1:00pm ET
Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BLUE
Yesterday
12:45pm ET
May 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BLUE
Yesterday
11:45am ET
Contact Levi & Korsinsky by May 28, 2024 Deadline to Join Class Action Against bluebird bio, Inc.(BLUE)
BLUE Financials
Key terms
Ad Feedback
BLUE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BLUE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
